Market revenue in 2023 | USD 33.3 million |
Market revenue in 2030 | USD 57.8 million |
Growth rate | 8.2% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase II |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 51.05% in 2023. Horizon Databook has segmented the UAE cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
In UAE, the clinical research sector is performing well, with many pharma companies investing in the studies. The Phase three and phase four studies are most common in UAE along with observational studies. The regulatory scenario in the country is favorable for clinical studies.
The Health Authority Abu Dhabi’s (HAAD) medical research sections promote world class research that improves health & quality of life while ensuring ethical conduct of research & protection of human subjects.
For instance, in December 2021, AstraZeneca and G42 Healthcare partnered to expand research and diagnostics in the UAE. The companies would focus on gathering real-world information and conducting clinical studies through G42 Healthcare's CRO. Phase three and phase four studies are most common in UAE along with observational studies.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into UAE cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account